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Serum bilirubin levels and risk of 
type 2 diabetes: results from two 
independent cohorts in middle-
aged and elderly Chinese
Jing Wang1,2, Yaru Li1, Xu Han1, Hua Hu1, Fei Wang1, Xiulou Li2, Kun Yang2, Jing Yuan1, 
Ping Yao1, Xiaoping Miao3, Sheng Wei3, Youjie Wang1, Weihong Cheng1, Yuan Liang1, 
Xiaomin Zhang1, Huan Guo1, Handong Yang2, Jianmin Yuan4,5, Woon-Puay Koh6, 
Frank B. Hu7, Tangchun Wu1, An Pan3 & Meian He1
Serum bilirubin is a potent endogenous antioxidant and has been identified as cardiovascular risk 
in cohort studies, while the relation to type 2 diabetes (T2D) in the elderly remains unclear. We 
investigated both cross-sectional and prospective associations between serum bilirubin levels and T2D 
risk in the Dongfeng-Tongji (DFTJ) cohort, and replicated the prospective findings in a nested case-
control study (509 cases and 509 controls) within the Singapore Chinese Health Study (SCHS). In the 
cross-sectional analysis of DFTJ cohort (15,575 participants with 2,532 diabetes cases), serum bilirubin 
levels (total, direct and indirect) increased in new on-set diabetes and decreased with the diabetic 
duration. In the longitudinal analysis of DFTJ cohort (772 incident diabetes cases during 4.5 years of 
follow-up among 12,530 diabetes-free participants at baseline), positive association was found between 
direct bilirubin and T2D risk comparing extreme quartiles, similar results were observed in the nested 
case-control study within SCHS. Total and indirect bilirubin levels were not significantly associated with 
T2D in either cohort. In conclusion, our findings do not support the protective association between 
serum bilirubin levels and incident T2D in the middle-aged and elderly adults; instead, direct bilirubin 
levels were associated with increased risk of T2D.
Diabetes has become a serious public health concern worldwide, affecting more than 415 million people in 
2015, and about one fourth of them were Chinese. More than 90% of diabetes cases are type 2 diabetes (T2D)1. 
Oxidative stress and inflammation have been implicated in the underlying pathogenesis2–4. Bilirubin, a potent 
antioxidant5,6, is one of the end products of heme catabolism in the system circulation, and shown to decrease the 
risk of cardiovascular disease in prospective studies7–9. Some cross-sectional studies have reported that bilirubin 
was negatively related to diabetic risk factors such as hypertension and metabolic syndrome10–12. Experimental 
studies in animal models suggested that bilirubin could protect beta cells from oxidative injury13,14 and enhance 
insulin sensitivity by decreasing oxidative stress and inflammation15–17.
However, in current cross-sectional studies18–21 and longitudinal studies22–25, the relation between bilirubin 
and dysglycemia remains controversial. Such discrepancies might be due to age differences. Serum bilirubin levels 
decreased with age in young adults26, and increased with age in middle-aged and elderly adults18,27. Moreover, 
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previous studies mainly focused on serum total bilirubin (TBil)18–20,22–25, which is the sum of direct bilirubin 
(DBil) and indirect bilirubin (IBil). As traditional index of liver disease, TBil, DBil, and IBil have different clinical 
implications28. When TBil is in normal range, higher DBil may indicate hepatocellular injury29. Several studies 
had reported that DBil had more significant relationship to metabolic syndrome21,30 and stroke31 than TBil and 
IBil. Therefore, it is important to distinguish the temporal associations between different measures of bilirubin 
(TBil, DBil or IBil) and diabetic risk.
Therefore, we conducted the current analysis using data from the Dongfeng-Tongji (DFTJ) cohort, a prospec-
tive cohort study in a middle-aged and elderly Chinese population. We first examined the cross-sectional relation 
between serum bilirubin levels (TBil, DBil, and IBil) and prevalent diabetes, and then evaluated the prospective 
associations of bilirubin levels with incident diabetes during the 4.5 years of follow-up period. To validate our 
longitudinal results, we further replicated the analysis using data from a nested case-control study within the 
Singapore Chinese Health Study (SCHS).
Results
The median (interquartile range) of serum TBil, DBil, and IBil levels was 13.3 (10.3–16.9), 3.7 (3.0–4.6), 9.5 
(7.1–12.4) μ mol/L, respectively. Baseline data according to the quartiles of TBil are presented in Table 1. 
Participants with higher serum TBil concentrations were more likely to be men, drinkers, never smokers, and 
with lower education levels. They also have elevated levels of AST, HDL, diastolic pressure, and lower levels of 
ALP (all Ptrend < 0.05).
In the DFTJ cohort, a total of 772 T2D cases were identified during 4.5 year (56,723 person-years) of 
follow-up, corresponding to an incidence rate of 13.6 per 1000 person-years. As shown in the Table 2, compared 
with those in the lowest quartile of DBil levels, the HRs (95% CIs) were 1.22 (0.98–1.52), 1.39 (1.12–1.72), and 
1.29 (1.03–1.61) for Q2–Q4 in the full adjusted model (Ptrend = 0.03). No significant relationship was observed for 
TBil (Ptrend = 0.27) or IBil (Ptrend = 0.70). In sensitive analysis, the associations changed to null when we excluded 
the participants with impaired fasting glucose (IFG, those with relatively higher bilirubin levels and more likely 
to develop diabetes) at baseline (Supplementary Table S1).
We further validated the relation of bilirubin levels and risk of T2D in the SCHS (Table 3). In this cohort, the 
mean duration between blood donation and diagnosis of T2D was 4.0 (SD 1.7) years. DBil levels were positively 
associated with the risk of T2D, and the OR (95% CI) across tertiles was 1.00 (reference), 1.68 (1.14–2.47), and 
Characteristics
Total bilirubin (μmol/L)
P for trend
Q1 Q2 Q3 Q4
2.8~ 10.3~ 13.3~ 16.9~34.2
N 3102 3168 3087 3173 —
Total bilirubin (μ mol/L) 8.6 (7,9.4) 11.6 (11.1,12.3) 14.8 (14.0,15.7) 19.2 (18.3,22.9) —
Direct bilirubin (μ mol/L ) 2.8 (2.5,3.3) 3.4 (3.1,3.8) 4.1 (3.5,4.5) 5.1 (4.3,5.9) —
Indirect bilirubin (μ mol/L) 5.8 (4.7,6.5) 8.2 (7.7,9) 10.7 (9.9,11.5) 14.3 (13.2,17.1) —
Age, years 60.9 (7.8) 61.9 (7.8) 62.6 (7.6) 63 (7.4) 0.019
Sex, men(%) 28.8 36.8 46.8 57.6 < 0.001
High school or above, (%) 36.7 35.4 34.8 32.9 < 0.001
Smoker, (%) 21.7 25.2 29.6 35.1 < 0.001
Drinker, (%) 19.4 23.6 28.3 34.4 0.004
Physical activity, (%) 87.7 89.4 90.3 89.8 0.032
FPG (mmol/L) 5.5 (0.6) 5.5 (0.6) 5.5 (0.6) 5.5 (0.6) 0.085
IFG (%) 43.4 43.2 45 47.3 0.18
ALP (U/L) 85 (69,102) 86 (72,102) 85 (70,101) 83 (69,98) 0.001
ALT (U/L) 19 (15,25) 19 (15,25) 19 (15,25) 20 (15,26) 0.45
AST (U/L) 22 (19,26) 22 (19,26) 23 (19,26) 23 (20,27) < 0.001
Total cholesterol (mmol/L) 5.2 (0.9) 5.2 (0.9) 5.2 (0.9) 5.1 (0.9) 0.89
Triglyceride (mmol/L) 1.2 (0.8,1.7) 1.2 (0.8,1.6) 1.1 (0.8,1.6) 1.1 (0.8,1.6) 0.057
High density lipoprotein (mmol/L) 1.4 (0.4) 1.5 (0.4) 1.5 (0.4) 1.5 (0.4) < 0.001
Low density lipoprotein (mmol/L) 3 (0.8) 3 (0.8) 3 (0.9) 3 (0.8) 0.021
Systolic pressure (mmHg) 126.2 (18.3) 127.3 (18.4) 127.4 (17.9) 128.3 (18.5) 0.19
Diastolic pressure (mmHg) 76.8 (10.5) 77.3 (10.9) 77.4 (10.8) 77.8 (10.8) 0.019
Overweight/obesity, (%) 48.7 50.7 50.4 50.7 0.61
Central obesity, (%) 44.4 41.4 39.3 37.6 0.67
Family history of diabetes, (%) 5.4 3.5 3.5 3.4 0.26
Hypertension, (%) 43.0 45.2 46 48.3 0.057
Table 1.  Baseline characteristics of the Dongfeng-Tongji cohort according to serum total bilirubin 
quartiles. Data are means (SD), percentage (%), or median (interquartile range); P-value was calculated after 
adjustment for age, sex except for itself. FPG, fasting plasma glucose; IFG, impared fasting glucose; ALP, alkaline 
phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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1.63 (1.03–2.58), respectively (Ptrend = 0.02) in the multivariate model. Similar to the DFTJ cohort, no significant 
relationship was observed for TBil (Ptrend = 0.74) or IBil (Ptrend = 0.86) with diabetes risk.
We further investigated the interaction between bilirubin levels and other covariates (sex, BMI, physical activ-
ity, drinking status, smoking status, and hypertension) on T2D risk in the DFTJ cohort. Although significant 
interactions were observed between smoking and bilirubin in the DFTJ cohort (Supplementary Figure S1), the 
interactions were not replicated in the SCHS (Supplementary Table S2).
We additionally examined the associations of bilirubin levels with T2D risk in the cross-sectional design based 
on the baseline data of Dongfeng-Tongji cohort at 2008 (n = 15,575). As Table 4 showed, the serum TBil, DBil, 
and IBil levels were inversely associated with the risk of T2D (Ptrend < 0.05) after adjustment for the traditional risk 
factors (model 1). Further adjustment for liver function and serum lipids diminished the associations to null. In 
addition, compared with the individuals with normal fasting glucose (n = 7,207), the IFG individuals (n = 5,836) 
had higher levels of bilirubin, and the new-onset diabetics (duration ≤ 1 year, n = 1,056, 41.2% of the diabetics) 
had the highest bilirubin levels (Fig. 1). In the next three diabetic groups (n = 454, 444 and 578, respectively), the 
bilirubin levels decreased with longer diabetic duration. Similarly, we found that the bilirubin levels were posi-
tively related to risk of T2D with 1-year duration but negatively with risk of T2D with more than 1-year duration 
(Supplementary Table S3).
Discussion
In the present study, we found that elevated serum DBil concentrations were associated with an increased 
risk of developing T2D independent of traditional diabetes risk factors in two independent cohort studies of 
middle-aged and elderly Chinese adults. In contrast, no significant associations were found with total and indi-
rect bilirubin levels. In addition, the serum bilirubin (TBil, DBil and IBil) levels were related to glucose metabolic 
status, and they increased in those with impaired fasting glucose and new-onset T2D, but decreased with the 
prolonged duration of diabetes.
Several cross-sectional studies have reported an inverse association between serum TBil and T2D18–20, while 
the results were not entirely consistent with some reporting no significant association between TBil and hyper-
glycemia21,30,32. Meanwhile, two cohort studies also reported an inverse association between TBil and T2D 
risk24,25. For example, a recent Mendelian randomization study in Dutch adults (n = 3,381) proposed that ele-
vated serum TBil was causally associated with a decreased risk of T2D24. The other 4-year retrospective cohort 
study in Korean men (n = 5,960) indicated that high TBil levels were protective for the development of T2D25. 
In contrast, our study and the other two East Asian prospective studies22,23 did not find significant associate 
between TBil and T2D. Age and race might two main factors contribute to the inconsistent findings. Serum 
bilirubin levels are increased in older people18,27. The average age in our study was relatively older. In addition, 
serum bilirubin concentrations in East Asia populations22,23 are higher than those in whites24. In the Dutch pop-
ulation, 95% of the individuals had TBil concentrations lower than 10 μ mol/L24; while in the present DFTJ cohort 
study, 75% of the individuals had TBil concentrations above 10 μ mol/L. Therefore, the results in this European 
cohort study could not be directly generalized to East Asian population. In the Korean study which reported 
Quartiles of serum bilirubin (μmol/L) P for 
trendQ1 Q2 Q3 Q4
Total bilirubin Range 2.8~ 10.3~ 13.3~ 16.9~34.2
Median 8.6 11.6 14.8 19.2
Cases/Person-years 185/14062.82 170/14371.89 224/13962.32 193/14326.08
Age-, sex- adjusted 1.00 (Ref) 0.91 (0.74–1.13) 1.22 (1.00–1.49) 1.03 (0.84–1.27) 0.31
Model 1 1.00 (Ref) 0.90 (0.73–1.11) 1.21 (1.00–1.48) 1.02 (0.83–1.26) 0.34
Model 2 1.00 (Ref) 0.92 (0.74–1.15) 1.28 (1.05–1.57) 1.04 (0.84–1.29) 0.27
Direct bilirubin Range 0.8~ 3.0~ 3.7~ 4.6~19.4
Median 2.6 3.3 4.1 5.3
Cases/Person-years 160/13090.16 190/14075.84 218/14923.01 204/14634.1
Age-, sex- adjusted 1.00 (Ref) 1.15 (0.93–1.42) 1.28 (1.04–1.58) 1.21 (0.98–1.50) 0.08
Model 1 1.00 (Ref) 1.15 (0.93–1.43) 1.31 (1.06–1.61) 1.23 (0.99–1.52) 0.06
Model 2 1.00 (Ref) 1.22 (0.98–1.52) 1.39 (1.12–1.72) 1.29 (1.03–1.61) 0.03
Indirect bilirubin Range 1.1~ 7.1~ 9.5~ 12.4~27.7
Median 5.7 8.1 10.7 14.3
Cases/Person-years 189/13865.8 170/14009.85 219/14627.99 194/14219.47
Age-, sex- adjusted 1.00 (Ref) 0.89 (0.73–1.10) 1.10 (0.90–1.34) 0.98 (0.80–1.20) 0.70
Model 1 1.00 (Ref) 0.88 (0.71–1.09) 1.11 (0.91–1.35) 0.96 (0.78–1.18) 0.83
Model 2 1.00 (Ref) 0.90 (0.73–1.11) 1.17 (0.96–1.43) 0.97 (0.79–1.20) 0.70
Table 2.  Associations of serum bilirubin levels and risk of type 2 diabetes incidence in Dongfeng-Tongji 
cohort (hazard ratio and 95% confidence interval). Model 1: adjusted for age, sex, body mass index, waist 
circumference, education level, smoking status, drinking status, physical activity, and family history of diabetes; 
Model 2: additionally adjusted for serum levels of alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, triglyceride, high density lipoprotein and history of hypertension.
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a protective association25, the concentrations of TBil (mean 20.1 μ mol/L) were much higher than some other 
Korean studies21,30.
Notably, in the current study, we found that the DBil levels were associated with an increased but not 
decreased risk of incident T2D in two independent cohort studies of Chinese adults. Bilirubin (including TBil, 
IBil, and DBil) is traditional liver function index28. Serum IBil is carried by albumin to liver where the hepatic 
enzyme UDP-glucuronyl transferase 1A1 converts IBil to DBil. When TBil is in normal range, higher DBil may 
indicate hepatocellular injury29. Increased liver enzymes were related to the hepatic insulin resistance in healthy 
individuals33. Thus, the positive association of DBil levels with T2D risk might reflect the relation between liver 
dysfunction and T2D risk.
Evidence from studies about heme oxygenase (HO) system34,35 might also support the increased risk of biliru-
bin with T2D. Increased activity of HO could elevate the heme catabolic products such as carbo monoxide, iron, 
and bilirubin34. HO-1 has been reported as a strong positive predictor of metabolic inflammation among obese 
insulin-resistance individuals and animals35,36. In population studies, plasma HO-1 concentrations were elevated 
in impaired glucose regulation individuals and new-onset type 2 diabetic patients37,38. The higher bilirubin levels 
might be a biomarker of oxidative stress and inflammation in pre- and new-onset diabetes. While in individuals 
with overt diabetes, HO system might adapt to the long-term oxidative stress induced by hyperglycemia and 
result in a decreased expression of HO-139. Meanwhile, reactive oxygen species generated by hyperglycemia in 
micro and macro vascular might lower the serum bilirubin concentrations. Therefore, long-term chronic hyper-
glycemia of diabetes might result in lower levels of serum bilirubin. Although bilirubin had been proven to be 
potent antioxidant5,6 and had the property of anti-inflammation15–17, the endogenous increased bilirubin levels 
are caused by the induction of HO through oxidative and inflammation reaction. More critically, we found serum 
bilirubin levels were influenced by glucose metabolic status: pre-diabetes and new-onset diabetes had higher bili-
rubin levels than individuals with normal fasting glucose, while the bilirubin levels decreased with the prolonged 
duration of diabetes (Fig. 1). This is consistent with a recent publication showing an inverse association between 
serum TBil and T2D duration40. This could partially explain why serum bilirubin levels were negatively associated 
with T2D risk in most cross-sectional studies18–20.
Strengths and limitations. The strengths of the present study include both cross-sectional and longitudi-
nal analyses base on the prospective cohort design and validation in another independent cohort; adjustment for 
multiple covariates including liver function; and evaluation of the bilirubin-diabetes association using TBil, DBil 
and IBil at the same time. More importantly, we found serum DBil was positively associated with incident T2D in 
two independent cohorts, indicating the robustness of the present results.
There are also several limitations of the present study. Firstly, although we speculate that the HO system 
played an important role in the bilirubin effects on T2D development, but we did not measure the levels of HO, 
and markers of inflammation and oxidative stress in the present population. However, previous studies have 
suggested that plasma HO-1 levels are positively associated with T2D risk37,38, lending support to the present 
findings. Secondly, the follow-up periods in DFTJ and SCHS cohorts were relatively short, and statistical power 
might be limited because of the small number of incident cases. Nonetheless, the effects of three type of bilirubin 
Bilirubin type
Tertiles of serum bilirubin levels (μmol/L) P for 
trendT1 T2 T3
Total bilirubin Range 4~ 9~ 11~44
Median 7 9 13
Cases/controls 169/165 156/147 184/197
Age adjusted model 1.00 (Ref) 1.03 (0.75–1.42) 0.91 (0.67–1.24) 0.46
Model 1 1.00 (Ref) 1.09 (0.78–1.54) 0.88 (0.63–1.24) 0.34
Model 2 1.00 (Ref) 1.02 (0.68–1.54) 0.94 (0.62–1.43) 0.74
Direct bilirubin Range 1~ 2~ 3~8
Median 1 2 3
Cases/controls 177/209 214/180 118/120
Age adjusted model 1.00 (Ref) 1.46 (1.09–1.97) 1.22 (0.85–1.74) 0.16
Model 1 1.00 (Ref) 1.41 (1.03–1.93) 1.27 (0.87–1.86) 0.14
Model 2 1.00 (Ref) 1.68 (1.14–2.47) 1.63 (1.03–2.58) 0.02
Indirect bilirubin Range 3~ 8~ 9~36
Median 6 8 11
Cases/controls 237/234 88/79 184/196
Age adjusted model 1.00 (Ref) 1.10 (0.77–1.58) 0.93 (0.70–1.23) 0.58
Model 1 1.00 (Ref) 1.15 (0.78–1.70) 0.91 (0.67–1.24) 0.52
Model 2 1.00 (Ref) 1.09 (0.68–1.72) 0.97 (0.67–1.40) 0.86
Table 3.  Associations of serum bilirubin levels and risk of type 2 diabetes in Singapore Chinese Health 
Study (Odds ratio and 95% confidence interval). Model 1: adjusted for age, BMI, education level, smoking 
status, drinking status, physical activity; Model 2: additionally adjusted for alkaline phosphatase, alanine 
aminotransferase, aspartate aminotransferase, triglyceride, high density lipoprotein, history of hypertension 
and fasting status.
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were similar in the two independent populations suggesting low probability of chance findings. Thirdly, we only 
measured serum bilirubin once at baseline, and the concentrations may not represent long-term exposure status. 
Finally, the current study was conducted in middle-aged and elderly Chinese population, and further studies with 
different ethnic and age populations are required to confirm our findings.
Conclusions
In summary, we found serum DBil concentrations were positively associated with the risk of incident T2D in 
middle-aged and elderly adults. Additional large and long-term prospective studies in different ethnic groups are 
warranted to establish the role of serum bilirubin in the T2D development.
Methods
Study population. The DFTJ cohort is an ongoing dynamic prospective cohort including 27,009 retirees 
who come from the Dongfeng Motor Corporation with an average age of 63.6 years at study inception in 200841. 
Each participant completed a semi-structured questionnaire including the socio-demographic, lifestyle, health 
status, and medical history, and also physical examination including fasting blood sample collection. Participants 
with available data of serum bilirubin and normal urobilirubin and urobilinogen were eligible for the present anal-
ysis (n = 23,482). We further excluded those with self-reported history of liver diseases and cancer (n = 1,633), 
abnormal levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase 
(ALP) (defined as values above the 95% reference levels; n = 2,466), and missing data for fasting glucose (n = 7). 
To rule out those who might potentially have Gilber syndrome, subjects with TBil above 34.2 μ mol/L were also 
excluded (n = 117)42. We further excluded subjects who reported to have coronary heart disease (CHD) or stroke 
(n = 3,684). The remained participants were 15,575. In 2013, a total of 14,973 eligible participants who attended 
the baseline survey were successfully followed. In the longitudinal analysis, we further excluded 2,443 individuals 
with diabetes at baseline, and 12,530 participants remained.
We further validated the results in a nested case-control study from the SCHS cohort. Details of the SCHS 
have been reported elsewhere43,44. Briefly, participants were all middle-aged and elderly Chinese in Singapore 
and free of diabetes at the time of blood collection between 1999 and 2004. They were contacted by telephone 
during the follow-up interview occurred in 2006–2010. A total of 509 incident diabetes cases were selected for 
the present analysis, and 509 controls were randomly selected from the remaining diabetes-free participants 
and matched on age (± 3 years), sex, dialect group (Cantonese, or Hokkien), and date (± 6 months) of blood 
collection. The detailed characteristics of the subjects in this nested case-control study were present in the 
Supplementary Table S4. All participants were free of CHD, stroke or cancer at baseline.
Quartiles of serum bilirubin (μmol/L)
P for trendQ1 Q2 Q3 Q4
Total bilirubin Range 2.8~ 10.2~ 13.2~ 16.9~34.2
Median 8.5 11.6 14.8 19.2
Cases/n 673/3805 616/3919 602/3917 641/3934
Age-, sex- adjusted 1.00 (Ref) 0.84 (0.74–0.95) 0.79 (0.70–0.9) 0.84 (0.74–0.95) 0.01
Model 1 1.00 (Ref) 0.85 (0.75–0.97) 0.80 (0.70–0.9) 0.84 (0.74–0.95) 0.01
Model 2 1.00 (Ref) 0.87 (0.76–0.98) 0.83 (0.73–0.94) 0.89 (0.78–1.01) 0.08
Model 3 1.00 (Ref) 0.90 (0.79–1.02) 0.86 (0.75–0.98) 0.92 (0.80–1.04) 0.19
Direct bilirubin Range 0.8~ 3.0~ 3.7~ 4.6~19.4
Median 2.6 3.3 4.1 5.3
Cases/n 593/3571 634/3901 667/4097 638/4006
Age-, sex- adjusted 1.00 (Ref) 0.94 (0.83–1.06) 0.91 (0.81–1.03) 0.86 (0.75–0.97) 0.02
Model 1 1.00 (Ref) 0.92 (0.81–1.05) 0.91 (0.80–1.03) 0.83 (0.73–0.95) 0.01
Model 2 1.00 (Ref) 0.94 (0.82–1.07) 0.94 (0.83–1.08) 0.89 (0.77–1.02) 0.11
Model 3 1.00 (Ref) 0.99 (0.86–1.13) 1.01 (0.89–1.16) 0.95 (0.83–1.09) 0.51
Indirect bilirubin Range 1.1~ 7.1~ 9.5~ 12.3~27.7
Median 5.7 8.1 10.7 14.3
Cases/n 678/3874 619/3846 586/3881 649/3974
Age-, sex- adjusted 1.00 (Ref) 0.88 (0.78–0.99) 0.79 (0.70–0.90) 0.87 (0.77–0.98) 0.01
Model 1 1.00 (Ref) 0.88 (0.78–1.00) 0.82 (0.72–0.93) 0.86 (0.76–0.97) 0.02
Model 2 1.00 (Ref) 0.90 (0.79–1.02) 0.86 (0.75–0.97) 0.90 (0.79–1.02) 0.11
Model 3 1.00 (Ref) 0.93 (0.81–1.05) 0.88 (0.77–1.00) 0.93 (0.81–1.06) 0.23
Table 4. Associations of serum bilirubin levels and risk of type 2 diabetes in the cross-sectional analysis 
of the Dongfeng-Tongji Cohort (n = 15,575). Model 1: adjusted for age, sex, body mass index, waist 
circumference, education level, smoking status, drinking status, physical activity, family history of diabetes, and 
history of hypertension; Model 2: additionally adjusted for alkaline phosphatase, alanine aminotransferase, and 
aspartate aminotransferase; Model 3: additionally adjusted for triglyceride and high density lipoprotein.
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Ethics statement. The DFTJ cohort study was approved by the Medical Ethics Committee of the School of 
Public Health, Tongji Medical College, and the Dongfeng General Hospital in the Dongfeng Motor Corporation. 
The SCHS cohort was approved by the Institutional Review Board of the National University of Singapore. The 
methods were carried out in accordance with the relevant guidelines. All subjects enrolled gave written informed 
consent for participation.
Laboratory measurements. In the DFTJ cohort, peripheral venous blood samples were collected after 
overnight fasting. Plasma glucose levels were measured with Aeroset automatic analyzer (by glucose oxidase 
method; Abbott Laboratories. Abbott Park, Illinois, USA). The serum bilirubin, lipids, hepatic function, and renal 
function were measured by the ARCHITECTCi8200 automatic analyzer (ABBOTT Laboratories. Abbott Park, 
Illinois, USA). In the SCHS, morning random blood samples were collected, and plasma lipids, hepatic enzymes, 
and bilirubin were measured via colorimetric method on a chemistry analyzer (AU5800 Analyzer, Beckman 
Coulter, Brea, CA).
T2D definition. In the DFTJ cohort, T2D was defined as having fasting plasma glucose (FPG) ≥ 7.0 mmol/L, 
according to the WHO criteria45, or having self-reported doctor-diagnosed diabetes or taking antidiabetic medi-
cations. In the SCHS, history of physician-diagnosed diabetes was asked at each follow-up interview by the ques-
tion: “Have you been told by a doctor that you have diabetes?” If the answer was “yes”, participants were further 
asked for the age at which they were first diagnosed. In a validation study of the SCHS cohort participants, 97% 
of the self-reported diabetes cases were confirmed to be valid, suggesting a very high positive predictive value46.
Statistical analysis. In the DFTJ cohort, baseline characteristics data were compared across quartiles of 
TBil. Categorical variables were expressed in percentages and continuous variables in mean (SD) or median 
(interquartile range). Covariate distributions across baseline TBil quartiles were compared using logistic regres-
sion models for categorical variables and ANOVA for continuous variables.
Follow-up time was calculated from baseline to the date of diagnosis of T2D, death, or the follow-up interview, 
whichever came first. Cox proportional hazards models were used to examine hazard ratio (HR) and confidence 
intervals (CIs) of T2D for each bilirubin quartile compared with the lowest quartile, with adjustment for age 
µ
Figure 1. Least square means of three types of bilirubin levels in different groups. Least square means 
were adjusted for age, sex, BMI, waist circumference, education level, smoking status, drinking status, physical 
activity, family history of diabetes, history of hypertension, alkaline phosphatase, alanine aminotransferase, 
aspartate aminotransferase, triglyceride, high density lipoprotein and fasting plasma glucose. Black 
square = total bilirubin; white square = direct bilirubin; white circles = indirect bilirubin. Diabetes group 1: 
duration ≤ 1 year; Diabetes group 2: duration > 1 year while ≤ 5 years; Diabetes group 3: duration > 5 year while 
≤ 10 years; Diabetes group 4: duration > 10 years.
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(continuous), sex, BMI (< 24 and ≥ 24 kg/m2), central obesity (binary variable defined as waist circumference ≥ 
85 cm in men or ≥ 80 cm in women), education (below secondary school, secondary school or higher), smok-
ing status (ever and never smoker), drinking status (ever and never drinker), physical activity (yes, no), family 
history of diabetes (yes, no), baseline history of hypertension (yes, no). Liver function measures (ALT, AST, and 
ALP), triglyceride, and high density lipoprotein (HDL) were treated as continuous variables and included in the 
final model. To test the linear trend across bilirubin quartiles, we assigned the median value to each quartile, and 
treated it as continuous variable in the model. Stratified analyses were performed according to sex, BMI category, 
smoking, drinking, and history of hypertension. We also calculated the HRs associated with per 1 SD increase in 
bilirubin. Likelihood ratio tests were conducted to examine interactions.
In the cross-sectional analysis of Dongfeng-Tongji cohort, logistical regression models were used to examine 
Odds ratios (OR) and 95% CIs of T2D for three types of bilirubin. To investigate the change of bilirubin levels 
among different glucose metabolic groups (individuals with normal fasting glucose, impaired fasting glucose, 
diabetes with different duration), we used generalized linear models to calculate least squares means of bilirubin 
levels among different groups. According to diabetes duration, T2D cases were classified into four groups: dura-
tion ≤ 1 year; 1 year < duration ≤ 5 years; 5 years < duration ≤ 10 years; and duration > 10 years.
In the nested case-control study from SCHS, participants were classified into three categories according to 
the levels of bilirubin because of relative small sample size and accuracy of the data (values were rounded to 
integral numbers from the lab). Conditional Logistic regression models were used to estimate ORs and 95% CIs. 
Covariates in model included age, BMI (< 24 and ≥ 24 kg/m2), education (below secondary school, secondary 
school or higher), smoking status (ever and never smokers), drinking status (ever and never drinkers), physical 
activity levels (< 0.5, ≥ 0.5 hours/week), continuous values of ALP, ALT, AST, triglyceride, and high density lipo-
protein, baseline history of hypertension, and fasting status. All statistical analyses were performed with SAS ver-
sion 9.4 (SAS Institute, Cary, North Carolina, USA). Two-sided P < 0.05 was considered as statistically significant.
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